These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 37865646)

  • 1. Soluble TREM2 ameliorates tau phosphorylation and cognitive deficits through activating transgelin-2 in Alzheimer's disease.
    Zhang X; Tang L; Yang J; Meng L; Chen J; Zhou L; Wang J; Xiong M; Zhang Z
    Nat Commun; 2023 Oct; 14(1):6670. PubMed ID: 37865646
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early increase of CSF sTREM2 in Alzheimer's disease is associated with tau related-neurodegeneration but not with amyloid-β pathology.
    Suárez-Calvet M; Morenas-Rodríguez E; Kleinberger G; Schlepckow K; Araque Caballero MÁ; Franzmeier N; Capell A; Fellerer K; Nuscher B; Eren E; Levin J; Deming Y; Piccio L; Karch CM; Cruchaga C; Shaw LM; Trojanowski JQ; Weiner M; Ewers M; Haass C;
    Mol Neurodegener; 2019 Jan; 14(1):1. PubMed ID: 30630532
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Soluble TREM2 ameliorates pathological phenotypes by modulating microglial functions in an Alzheimer's disease model.
    Zhong L; Xu Y; Zhuo R; Wang T; Wang K; Huang R; Wang D; Gao Y; Zhu Y; Sheng X; Chen K; Wang N; Zhu L; Can D; Marten Y; Shinohara M; Liu CC; Du D; Sun H; Wen L; Xu H; Bu G; Chen XF
    Nat Commun; 2019 Mar; 10(1):1365. PubMed ID: 30911003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Soluble TREM2 inhibits secondary nucleation of Aβ fibrillization and enhances cellular uptake of fibrillar Aβ.
    Belsare KD; Wu H; Mondal D; Bond A; Castillo E; Jin J; Jo H; Roush AE; Pilla KB; Sali A; Condello C; DeGrado WF
    Proc Natl Acad Sci U S A; 2022 Feb; 119(5):. PubMed ID: 35082148
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TREM2 modifies microglial phenotype and provides neuroprotection in P301S tau transgenic mice.
    Jiang T; Zhang YD; Chen Q; Gao Q; Zhu XC; Zhou JS; Shi JQ; Lu H; Tan L; Yu JT
    Neuropharmacology; 2016 Jun; 105():196-206. PubMed ID: 26802771
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuroimaging biomarkers and CSF sTREM2 levels in Alzheimer's disease: a longitudinal study.
    Nabizadeh F; Seyedmirzaei H; Karami S
    Sci Rep; 2024 Jul; 14(1):15318. PubMed ID: 38961148
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TREM2 ectodomain and its soluble form in Alzheimer's disease.
    Yang J; Fu Z; Zhang X; Xiong M; Meng L; Zhang Z
    J Neuroinflammation; 2020 Jul; 17(1):204. PubMed ID: 32635934
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interleukin-3 is associated with sTREM2 and mediates the correlation between amyloid-β and tau pathology in Alzheimer's disease.
    Wang ZB; Ma YH; Sun Y; Tan L; Wang HF; Yu JT;
    J Neuroinflammation; 2022 Dec; 19(1):316. PubMed ID: 36578067
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CSF sTREM2 in delirium-relation to Alzheimer's disease CSF biomarkers Aβ42, t-tau and p-tau.
    Henjum K; Quist-Paulsen E; Zetterberg H; Blennow K; Nilsson LNG; Watne LO
    J Neuroinflammation; 2018 Nov; 15(1):304. PubMed ID: 30390679
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TREM2 expression in the brain and biological fluids in prion diseases.
    Diaz-Lucena D; Kruse N; Thüne K; Schmitz M; Villar-Piqué A; da Cunha JEG; Hermann P; López-Pérez Ó; Andrés-Benito P; Ladogana A; Calero M; Vidal E; Riggert J; Pineau H; Sim V; Zetterberg H; Blennow K; Del Río JA; Marín-Moreno A; Espinosa JC; Torres JM; Sánchez-Valle R; Mollenhauer B; Ferrer I; Zerr I; Llorens F
    Acta Neuropathol; 2021 Jun; 141(6):841-859. PubMed ID: 33881612
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cerebrospinal fluid soluble TREM2 levels in frontotemporal dementia differ by genetic and pathological subgroup.
    Woollacott IOC; Nicholas JM; Heslegrave A; Heller C; Foiani MS; Dick KM; Russell LL; Paterson RW; Keshavan A; Fox NC; Warren JD; Schott JM; Zetterberg H; Rohrer JD
    Alzheimers Res Ther; 2018 Aug; 10(1):79. PubMed ID: 30111356
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Variants in the MS4A cluster interact with soluble TREM2 expression on biomarkers of neuropathology.
    Winfree RL; Nolan E; Dumitrescu L; Blennow K; Zetterberg H; Gifford KA; Pechman KR; Seto M; Petyuk VA; Wang Y; Schneider J; Bennett DA; Jefferson AL; Hohman TJ;
    Mol Neurodegener; 2024 May; 19(1):41. PubMed ID: 38760857
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TREM2 splice isoforms generate soluble TREM2 species that disrupt long-term potentiation.
    Moutinho M; Coronel I; Tsai AP; Di Prisco GV; Pennington T; Atwood BK; Puntambekar SS; Smith DC; Martinez P; Han S; Lee Y; Lasagna-Reeves CA; Lamb BT; Bissel SJ; Nho K; Landreth GE
    Genome Med; 2023 Feb; 15(1):11. PubMed ID: 36805764
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cerebrospinal Fluid sTREM2 in Alzheimer's Disease Is Associated with Both Amyloid and Tau Pathologies but not with Cognitive Status.
    Li TR; Lyu DY; Liu FQ;
    J Alzheimers Dis; 2022; 90(3):1123-1138. PubMed ID: 36213998
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased cerebrospinal fluid soluble TREM2 concentration in Alzheimer's disease.
    Heslegrave A; Heywood W; Paterson R; Magdalinou N; Svensson J; Johansson P; Öhrfelt A; Blennow K; Hardy J; Schott J; Mills K; Zetterberg H
    Mol Neurodegener; 2016 Jan; 11():3. PubMed ID: 26754172
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of the minimal active soluble TREM2 sequence for modulating microglial phenotypes and amyloid pathology.
    Sheng X; Yao Y; Huang R; Xu Y; Zhu Y; Chen L; Zhang L; Wang W; Zhuo R; Can D; Chang CF; Zhang YW; Xu H; Bu G; Zhong L; Chen XF
    J Neuroinflammation; 2021 Dec; 18(1):286. PubMed ID: 34893068
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early changes in CSF sTREM2 in dominantly inherited Alzheimer's disease occur after amyloid deposition and neuronal injury.
    Suárez-Calvet M; Araque Caballero MÁ; Kleinberger G; Bateman RJ; Fagan AM; Morris JC; Levin J; Danek A; Ewers M; Haass C;
    Sci Transl Med; 2016 Dec; 8(369):369ra178. PubMed ID: 27974666
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dynamic changes of CSF sTREM2 in preclinical Alzheimer's disease: the CABLE study.
    Ma LZ; Tan L; Bi YL; Shen XN; Xu W; Ma YH; Li HQ; Dong Q; Yu JT
    Mol Neurodegener; 2020 Apr; 15(1):25. PubMed ID: 32276587
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of TREM2 in Alzheimer's Disease and its Consequences on β- Amyloid, Tau and Neurofibrillary Tangles.
    Singh AK; Mishra G; Maurya A; Awasthi R; Kumari K; Thakur A; Rai A; Rai GK; Sharma B; Kulkarni GT; Singh SK
    Curr Alzheimer Res; 2019; 16(13):1216-1229. PubMed ID: 31481003
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Soluble TREM2 and biomarkers of central and peripheral inflammation in neurodegenerative disease.
    Bekris LM; Khrestian M; Dyne E; Shao Y; Pillai JA; Rao SM; Bemiller SM; Lamb B; Fernandez HH; Leverenz JB
    J Neuroimmunol; 2018 Jun; 319():19-27. PubMed ID: 29685286
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.